Fair enough. A (probably weighted average) prior on his pancreatic neuroendocrine tumor puts the 5 year survival rate at 54% instead of 9%. [1] It appears there are more pancreatic NET cases in the least favorable, "distant" SEER classification.

Nevertheless, there can be more factors at play than distrust of the medical community. Some people may want to live out the rest of their lives free from the harsh side effects of chemotherapy, for example. I wouldn't use his cancer treatment decisions to argue that tech elites make bad choices in the face of information, to bring us back to the broader discussion.

[1] https://www.cancer.org/cancer/pancreatic-neuroendocrine-tumo...